MDXG vs. AORT, FNA, ATRC, KIDS, ATRI, SILK, TMCI, SIBN, EMBC, and NVCR
Should you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include Artivion (AORT), Paragon 28 (FNA), AtriCure (ATRC), OrthoPediatrics (KIDS), Atrion (ATRI), Silk Road Medical (SILK), Treace Medical Concepts (TMCI), SI-BONE (SIBN), Embecta (EMBC), and NovoCure (NVCR). These companies are all part of the "surgical & medical instruments" industry.
MiMedx Group (NASDAQ:MDXG) and Artivion (NYSE:AORT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.
In the previous week, MiMedx Group had 32 more articles in the media than Artivion. MarketBeat recorded 37 mentions for MiMedx Group and 5 mentions for Artivion. MiMedx Group's average media sentiment score of 0.52 beat Artivion's score of 0.46 indicating that MiMedx Group is being referred to more favorably in the media.
MiMedx Group has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Artivion has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500.
MiMedx Group received 22 more outperform votes than Artivion when rated by MarketBeat users. Likewise, 77.27% of users gave MiMedx Group an outperform vote while only 66.67% of users gave Artivion an outperform vote.
MiMedx Group has a net margin of 18.63% compared to Artivion's net margin of -8.67%. MiMedx Group's return on equity of 39.42% beat Artivion's return on equity.
MiMedx Group presently has a consensus target price of $12.25, indicating a potential upside of 66.21%. Artivion has a consensus target price of $23.50, indicating a potential upside of 12.28%. Given MiMedx Group's higher possible upside, equities analysts plainly believe MiMedx Group is more favorable than Artivion.
MiMedx Group has higher earnings, but lower revenue than Artivion. Artivion is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 86.4% of Artivion shares are owned by institutional investors. 19.9% of MiMedx Group shares are owned by insiders. Comparatively, 8.1% of Artivion shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
MiMedx Group beats Artivion on 14 of the 17 factors compared between the two stocks.
Get MiMedx Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiMedx Group Competitors List
Related Companies and Tools
